Novo Nordisk CEO Mike Doustdar said on Monday as many as 1.5 million patients in the U.S. may be using compounded versions of ...
1don MSN
Healthy returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference
Novo Nordisk's CEO spoke about GLP-1 pricing and Pfizer's CEO spoke about the company's obesity ambitions while at the ...
The past year was one of turbulence and change at Novo Nordisk, and, while the Danish drugmaker still has its work cut out ...
Compounding pharmacy sues Eli Lilly and Novo Nordisk alleging antitrust violations to restrict compounded GLP-1 medication access and limit competition.
Novo Nordisk CEO Mike Doustdar said on Tuesday the drugmaker expects headwinds in its international operations in 2026, as ...
Pharmaceutical Technology on MSN
Novo Nordisk Foundation pours $850m into European life sciences economy
The funding aims to encourage innovation in Europe amid concerns that innovation across the continent is lagging behind China ...
Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable ...
A compounding pharmacy has filed a lawsuit accusing Eli Lilly and Novo Nordisk of using anticompetitive tactics to prevent it ...
Novo Nordisk ( NVO +1.68%) was once the top player in the weight loss drug market. The company's medicine, Wegovy, ...
Historic grant will fund BioInnovation Institute expansion across Europe through 2035, targeting startups, jobs, and ...
Novo Nordisk A/S (NOVO:CA) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 12:45 PM ESTCompany ...
The Novo Nordisk Foundation announced it was giving an additional $850 million to an institute to help commercialize ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback